Septic Shock
Conditions
Keywords
Sepsis, Critically ill, Intensive care medicine, CytoSorb, Hemoadsorption, Pharmacokinetic
Brief summary
This prospective randomized single center study investigates to what extent the removal of elevated cytokine levels by hemoadsorption has a positive effect on the treatment of patients in septic shock by stabilizing the circulatory situation.
Detailed description
The term sepsis refers to a clinical syndrome in which a dysregulation of the host's inflammatory reaction to infection leads to a life-threatening of organ dysfunctions. Sepsis and septic shock are major causes of death in intensive care units worldwide. The clinical picture of septic shock, the most severe form of sepsis, leads to uncontrolled production and release of a large number of proinflammatory cytokines and mediators, the cytokine storm. Septic shock is accompanied by a massive increase in mortality of up to 60%. This high mortality rate is due to a lack of current treatment options. The early recognition of the disease and its immediate treatment are decisive for successful therapy and the survival of those affected. The most important therapeutic steps, apart from focus control by antibiotics and surgical intervention, are the stabilization of the affected organ systems, in particular the circulatory system and the respiratory system. As an extracorporeal and non-specific procedure for the interruption of the cytokine storm, hemoadsorption by means of CytoSorb adsorbers may be an intervention, which has already demonstrated its basic effectiveness in the treatment of septic and cardiosurgical patients.
Interventions
DEVICECytoSorb-Therapy
Additional use of Cytosorb-Adsorber in patients with septic shock and need for continuous renal replacement therapy
Sponsors
CytoSorbents, Inc
Universitätsklinikum Hamburg-Eppendorf
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Refractory septic shock * Need for Norepinephrine ≥ 0.25 µg/kg/min * IL6 ≥ 1000 ng/l * Indication for CRRT
Exclusion criteria
* Sepsis due to pulmonary or urogenital causes * Onset of septic shock longer than 36 hours * Liver cirrhosis Child Pugh C * do not resuscitate-order * expected survival \< 14 days * participation in another interventional trial * Pregnancy or breastfeeding * Lack of consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of patients with a reduction of catecholamine dose of at least 25% within the first 48 hours of treatment | 48 hours | Percentage of patients with a reduction of catecholamine dose of at least 25% compared to baseline for at least 6 hours within the first 48 hours of treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Lactate clearance | 10 days | Improving lactate clearance by lowering serum lactate levels |
| Renal replacement therapy | 10 days | Time with need for renal replacement therapy |
| Percentage of patients with a reduction of catecholamine dose of at least 25% within the first 24 hours of treatment | 24 hours | Percentage of patients with a reduction of catecholamine dose of at least 25% compared to baseline for at least 6 hours within the first 48 hours of treatment. |
| End of septic shock | 10 days | Time until shock resolution |
| ICU length of stay | 90 days | ICU length of stay |
| Time on mechanical ventilation | 10 days | Time on mechanical ventilation |
| Cumulative catecholamine dose | 10 days | Cumulative catecholamine dose |
| Change in organ dysfunction | 10 days | Change in organ dysfunction based on Sequential Organ Failure Assessment (SOFA) Score The SOFA score is made of 6 variables, each representing an organ system. Each organ system is assigned a point value from 0 (normal) to 4 (high degree of dysfunction/failure) The worst physiological variables were collected serially every 24 hours of a patient's ICU admission. The worst measurement was defined as the measure that correlated to the highest number of points. The SOFA score ranges from 0 to 24. |
| Serum levels of administered anti-infectives | 3 days | Serum drug Levels of pre and post filter and adsorber system on day 1-3 while CytoSorb therapy (sampling: t 0, 1, 2, 6, 8, 12, 24 h after CytoSorb initiation) |
| Change of plasma Interleukin-6 (IL6) level | 10 days | Change of plasma Interleukin-6 (IL6) level |
| Change of plasma Interleukin-10 (IL10) level | 10 days | Change of plasma Interleukin-10 (IL10) level |
| Change of plasma Procalcitonin (PCT) level | 10 days | Change of plasma Procalcitonin (PCT) level |
| Change of HLA-DR level | 10 days | Change of HLA-DR (Human Leukocyte Antigen - DR isotype) level of monocytes |
| Change of TNF alpha level after ex-vivo stimulation | 10 days | Change of TNF-alfa level (Tumor Necrosis Factor alpha) level after LPS (Lipopolysaccharides) stimulation as sign of monocytic immunocompetence |
| Overall and ICU mortality | 90 days | Overall and ICU mortality |
Countries
Germany
Contacts
Backup ContactAxel Nierhaus, MD
Primary ContactDominik Jarczak, MD
Outcome results
None listed